Free tool
FAERS Monitor: Zilretta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208845 or its brand name (Zilretta, Triamcinolone Acetonide). Reports on generic versions are filed under their own applications.
Reports
864
Serious
179
21% of reports
Hospitalization
85
Death reported
10
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- recalled product administered226
- arthralgia126
- drug ineffective78
- no adverse event78
- joint swelling47
- therapeutic response shortened44
- pain41
- blood glucose increased35
- headache29
- arthritis bacterial28
- off label use27
- blood pressure increased22
- gait disturbance22
- joint effusion20
- muscle spasms18
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 36 |
| 2019 | 122 |
| 2020 | 95 |
| 2021 | 85 |
| 2022 | 77 |
| 2023 | 57 |
| 2024 | 310 |
| 2025 | 67 |
| 2026 | 15 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,295 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| recalled product administeredSignal | 226 | 590.8 | 527.2 | 129,406 |
| arthritis bacterialSignal | 28 | 167.2 | 116.0 | 4,432 |
| joint effusionSignal | 20 | 70.8 | 45.9 | 1,304 |
| therapeutic response shortenedSignal | 44 | 32.3 | 24.2 | 1,305 |
| no adverse eventSignal | 78 | 10.5 | 8.5 | 665 |
| joint swellingSignal | 47 | 9.5 | 7.2 | 350 |
| arthralgiaSignal | 126 | 7.4 | 6.3 | 702 |
| blood glucose increasedSignal | 35 | 4.5 | 3.3 | 93 |
| blood pressure increasedSignal | 22 | 3.5 | 2.3 | 37 |
| gait disturbanceSignal | 22 | 2.8 | 1.9 | 24 |
| muscle spasmsSignal | 18 | 2.4 | 1.5 | 13 |
| pain | 41 | 1.6 | 1.2 | 10 |
| drug ineffective | 78 | 1.4 | 1.2 | 11 |
| headache | 29 | 1.1 | 0.8 | 0 |
| off label use | 27 | 0.8 | 0.5 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.